Instrument Inactif

Gouvernance Progenics Pharmaceuticals, Inc.

US7431871067

Recherche biotechnologique et médicale

Comité Exécutif: Progenics Pharmaceuticals, Inc.

Dirigeant

Fonctions occupéesDepuis

David Mims

62 ans

Chief Executive Officer

Composition du Conseil d'Administration: Progenics Pharmaceuticals, Inc.

Administrateur	ComitésDepuis

Anciens Dirigeants et Administrateurs: Progenics Pharmaceuticals, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Jessica Jensen

Chief Tech/Sci/R&D Officer

01/02/2018

01/08/2020

Gérard Ber

Director/Board Member	08/11/2019	19/06/2020
Independent Dir/Board Member	08/11/2019	19/06/2020

Karen Ferrante

Director/Board Member	29/01/2014	19/06/2020
Independent Dir/Board Member	29/01/2014	19/06/2020

Bradley Campbell

Director/Board Member	01/06/2016	19/06/2020
Independent Dir/Board Member	01/06/2016	19/06/2020

Ann MacDougall

Director/Board Member	08/11/2019	15/11/2019
Chairman	15/11/2019	19/06/2020

Eric Ende

Director/Board Member

08/11/2019

19/06/2020

Patrick Fabbio

Comptroller/Controller/Auditor	16/11/2015	27/03/2020
Director of Finance/CFO	16/11/2015	27/03/2020
Corporate Secretary	-	27/03/2020

Mark Robert Baker

Director/Board Member	01/03/2011	11/11/2019
Chief Executive Officer	01/03/2011	11/11/2019
General Counsel	20/06/2005	01/01/2008
President	17/09/2009	01/03/2011
Corporate Secretary	20/06/2005	01/01/2008

David Scheinberg

Director/Board Member	01/01/1996	08/11/2019
Independent Dir/Board Member	01/01/1996	08/11/2019

Nicole S. Williams

Director/Board Member	01/01/2007	17/10/2019
Chairman	17/10/2019	08/11/2019
Independent Dir/Board Member	01/01/2007	08/11/2019

Michael Kishbauch

Director/Board Member	01/09/2013	17/10/2019
Independent Dir/Board Member	01/09/2013	17/10/2019

Peter J. Crowley

Director/Board Member	29/01/2009	14/06/2010
Chairman	14/06/2010	17/10/2019
Independent Dir/Board Member	29/01/2009	17/10/2019

Asha Das

Chief Tech/Sci/R&D Officer

02/01/2019

Nitya Ray

Corporate Officer/Principal

01/02/2001

01/10/2018

Jeffrey D. Summer

Chief Tech/Sci/R&D Officer	-	29/06/2018
Corporate Officer/Principal	01/05/2015	-

Thomas Strack

Chief Tech/Sci/R&D Officer

01/09/2015

01/01/2018

Syed Mahmood

Chief Tech/Sci/R&D Officer

01/09/2017

Aseem Anand

Corporate Officer/Principal

01/01/2017

Sheldon Hirt

General Counsel

01/07/2015

02/09/2016

Bryce V. Tenbarge

Corporate Officer/Principal

22/08/2016

Angelo William Lovallo

Comptroller/Controller/Auditor	01/01/2008	29/12/2015
Director of Finance/CFO	01/10/2012	16/11/2015
Treasurer	01/01/2008	29/12/2015

Robert J. Israel

Chief Tech/Sci/R&D Officer	01/10/1994	02/07/2015
Corporate Officer/Principal	02/07/2015	02/07/2015

Hagop Youssoufian

Chief Tech/Sci/R&D Officer

01/07/2013

19/09/2014

Stephen P. Goff

Director/Board Member	01/01/1993	11/09/2013
Independent Dir/Board Member	01/01/1993	11/09/2013

Kurt W. Briner

Director/Board Member	14/06/2010	12/06/2013
Chairman	01/01/1998	14/06/2010
Independent Dir/Board Member	01/01/1998	12/06/2013

Charles A. Baker

Director/Board Member	01/01/1994	12/06/2013
Independent Dir/Board Member	01/01/1994	12/06/2013

Benedict Osorio

Corporate Officer/Principal	01/07/2005	30/09/2012
Chief Operating Officer	-	-
Corporate Officer/Principal	-	-

Robert A. McKinney

Chief Operating Officer	01/01/1992	13/07/2009
Director of Finance/CFO	01/01/1992	30/09/2012
Public Communications Contact	26/06/2009	10/07/2009
Corporate Secretary	01/01/1992	30/09/2012
Treasurer	01/01/1992	23/07/2012

Mark Foote Dalton

Director/Board Member	01/01/1990	13/06/2012
Independent Dir/Board Member	01/01/1990	13/06/2012

James Garrison

Corporate Officer/Principal

01/01/2012

Laura Politi

Human Resources Officer

01/01/2004

01/01/2012

Thomas A. Boyd

Corporate Officer/Principal

01/01/2000

13/08/2010

Richard W. Krawiec

Public Communications Contact

01/02/2001

01/12/2009

Paul Jacobson

Chairman

01/01/1990

20/11/2008

Alton B. Kremer

Chief Tech/Sci/R&D Officer

01/10/2004

20/05/2008

David E. Martin

General Counsel	23/07/2012	-
Corporate Officer/Principal	19/09/2011	23/07/2012

Tage Ramakrishna

Chief Tech/Sci/R&D Officer	14/07/2009	-
Corporate Officer/Principal	10/07/2009	14/07/2009

Vivien Wong

Corporate Officer/Principal

01/09/2007

01/01/2021

Walter Capone

Corporate Officer/Principal

08/01/2007

Lynn M. Bodarky

Sales & Marketing

01/02/2004

01/01/2007

Ronald J. Prentki

President

01/01/2005

Ann Marie Assumma

General Counsel	14/07/2009	-
Corporate Officer/Principal	10/07/2009	14/07/2009

David Gionco

Director of Finance/CFO

01/08/2004

Philip K. Yachmetz

General Counsel	01/01/2000	01/01/2004
Corporate Secretary	01/01/2000	01/01/2004

Meryl J. Longval

Chief Operating Officer

01/01/2002

Joel D. Sendek

Corporate Officer/Principal

01/01/1992

31/12/1996

William C. Olson

Chief Tech/Sci/R&D Officer

01/05/1994

Paul J. Maddon

Director/Board Member	10/03/2011	-
Chief Tech/Sci/R&D Officer	01/01/1988	20/03/2012
Founder	09/06/2010	-
President	01/01/1988	10/03/2011

Melissa Downs

Investor Relations Contact

Burt Adelman

Director/Board Member

Abhijeet Lele

Corporate Officer/Principal

Dory A. Kurowski

Public Communications Contact

Peter Kleinhenz

Corporate Officer/Principal

Dory A. Lombardo

Public Communications Contact

09/06/2010

Kathleen Fredriksen

Investor Relations Contact	-	-
Corporate Officer/Principal	-	03/09/2013

John W. Babich

Corporate Officer/Principal

Elaine Richardson

Corporate Officer/Principal

Brian Ruby

Corporate Officer/Principal

Amy Martini

Corporate Officer/Principal

04/09/2013

Suketu Sanghvi

Corporate Officer/Principal

Betty Manocchi

Corporate Officer/Principal

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	1
Femme	0

Dont comité exécutif

Homme	1
Femme	0

Dont Administrateurs

Homme	0
Femme	0

Progenics Pharmaceuticals, Inc. est engagée dans le développement de médicaments et d'autres produits destinés à cibler et à traiter le cancer. Le pipeline de la société comprend des agents thérapeutiques conçus pour cibler le cancer (AZEDRA et 1095) ; des agents d'imagerie ciblant l'antigène de la membrane spécifique de la prostate (PSMA) pour le cancer de la prostate (1404 et PyL), et des outils d'analyse d'imagerie. Il comprend également un produit commercial, RELISTOR (bromure de méthylnaltrexone) pour la constipation induite par les opioïdes. AZEDRA est un produit candidat radiothérapeutique en cours de développement pour le traitement du phéochromocytome et du paragangliome malins et/ou récurrents, des tumeurs rares situées respectivement dans les glandes surrénales et en dehors des glandes surrénales. RELISTOR est un traitement de la constipation induite par les opioïdes. PyL est un agent d'imagerie par TEP (topographie par émission de positons) fluorée ciblant la PSMA, en phase clinique, pour le cancer de la prostate. PSMA TTC est un anticorps thérapeutique ciblant la PSMA et marqué au thorium-227.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société